TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Biomedicine: Policy
Biomedicine: Science
Biomedicine: Industry Trends
Biomedicine: Geopolitics
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Akeso’s new immunotherapy drug called ivonescimab allowed half of its patients to go 11.1 months without their condition worsening. Photo: Shutterstock
Medicine

Akeso shares slump despite second China approval for lung cancer drug

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.

Venture capital market

China life sciences-focused Dalton Venture expands operations to Hong Kong

Biomedicine: Geopolitics

Hutchmed weighs cancer drug’s supply-chain options amid trade war

videocam
New medical drugs

Trump’s tariffs: will Chinese pharmaceutical industry feel the pain?

With biotech firms caught in the crosshairs of Trump’s tariffs, the levy could prove to be a boon for domestic producers but a bane for exporters.

videocam
6
Employees of Jiangxi Banbiantian Pharmaceutical pack medicines at the company’s plant in Jiangxi province. Photo: VCG via Getty Images
Biomedicine: Geopolitics

US report highlights China’s biotech rise, urges action to boost local industry

China is ‘quickly ascending to biotechnology dominance’ and the US must ‘take swift action in the next three years’, the report says.

4
Biomedicine: Industry Trends

China’s biotech firms record surge in overseas licensing deals in first quarter

Chinese drug makers landed 33 licensing deals with overseas pharmaceutical firms, with transactions totalling US$36.2 billion.

Advertisement
Advertisement
Advertisement
Science

What if curing cancer could cost 99% less in China?

Chinese biotech start-ups are going up against Western drug makers – and they could win.

videocam
38
Illustration: Brian Wang
United States

Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US rivalry

Akeso’s immunotherapy drug allowed half of its patients to go 11.1 months without their condition worsening.

18
Cancer

Groundbreaking cancer therapies are the goal for this biotech innovator

PostMag talks to 5 women innovators at the top of their game and pushing the boundaries of scientific discovery: here we meet Gina Jiang, managing director of the Hong Kong Institute of Biotechnology.

Artificial intelligence

AI-driven blood analysis may be the key to unlocking cancer’s secrets

AI helps researchers recognise patterns in the gene fragments they find in blood plasma, sparking a revolution in the field of epigenetics.

videocam
Professor Dennis Lo Yuk-ming, the founder of the Centre for Novostics at the Hong Kong Science and Technology Park on 7 January 2025. Photo: Jonathan Wong
China technology

Opinion | In tech war, China is gunning for mass adoption over premium innovation

From artificial intelligence and biotech to autonomous driving, China is disrupting the traditional high-cost model of proprietary innovation.

videocam
Illustration: Craig Stephens
Biomedicine: Industry Trends

Hong Kong biotech start-up Alephoson eyes global trial for eye-drug delivery

Hong Kong biotech start-up works with university partners to conduct global clinical trials studying prevalent eye diseases.

US-China relations

US can keep edge over China aviation by staying integrated with it: expert

Testimony in advisory body hearing also heard stark warnings about China’s biotechnology advances.

videocam
New medical drugs

ClouDr shares rise on DeepSeek integration with medical AI platform

Chinese company says DeepSeek’s AI model will enhance data mining in its platform, delivering efficiency to hospitals and pharmacies.

videocam
ClouDr’s medical AI platform enables remote consultations and prescriptions. Photo: Shutterstock
Biomedicine: Industry Trends

Chinese biotech firms cash in on promising drug discoveries via licensing

China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.

videocam
The value of Chinese biotech development deals, mostly out-licensing, rose 68 per cent year on year in the first nine months of last year to US$36.6 billion. Photo: Shutterstock
Artificial intelligence

Video | AI-driven firm aims to transform drug discovery

Chief scientific officer at XtalPi says AI can cut average drug discovery times to one to two years

Artificial intelligence

AI-driven drug discovery aided by Greater Bay Area integration, firm says

XtalPi says AI is reducing drug discovery times to two years from four.

videocam
Advertisement
Advertisement
Advertisement
Biomedicine: Science

CR Pharma, NAMI join forces to fight Alzheimer’s with Pfizer cancer drug

Palbociclib, developed by Pfizer for certain types of advanced breast cancer, was approved for sale in 2015.

Hong Kong’s Nano and Advanced Materials Institute. Photo: innovationhub.hk
US-China relations

China’s WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.

New medical drugs

Novel drug awaits Hong Kong diabetics suffering from debilitating eye disease

Oculis’ OCS-01 eye drops, currently in phase 3 trials for diabetic macular edema, can be an alternative to injection, CEO says.

videocam
Wuxi AppTec

WuXi AppTec, WuXi Biologics surge on slimmer chances of Biosecure Act’s passage

The bill’s absence from the proposed amendments to the US National Defence Authorisation Act comes as a reprieve for the two biotech firms.

WuXi AppTec says it provides US lawmakers and federal agencies with information about the services it provides to customers in the US and around the world. Photo: Shutterstock
Biomedicine: Science

Hong Kong residents reticent to get latest Covid-19 jab, Moderna survey finds

About 52 per cent of Hong Kong respondents said they were willing to get the updated vaccine, compared with 58 per cent in Singapore.

Moderna’s survey results indicate a “growing complacency” even as coronavirus variants continue to evolve. Photo: Shutterstock
Biomedicine: Industry Trends

China welcomes new US$1 billion Sanofi project in Beijing

Sanofi’s latest capital outlay in China will cover the development of a new insulin plant in the nation’s capital.

Biomedicine: Science

Hong Kong start-up eyes global pest control market with scent-based products

Plasticvore is a two-year old biotech start-up offering alternative, humane solutions to controlling and eliminating pests, founder says.

videocam
Health & Fitness

China expands health insurance coverage with 91 new drugs, innovative treatments

The health authority shows its support for novel drugs, while driving tough bargains with pharmaceutical firms on prices.

videocam
China has added dozens of new drugs to its medical insurance reimbursement list. Photo: Getty Images
SCMP Highlights

Recap | ‘Promising’ steps to HIV vaccine, Trump tariffs threaten profits: 5 biotech stories

Discover breakthroughs in the biotech world, from a potential HIV cure to China’s booming drug market and innovative coronavirus treatments, in some of our latest stories.

A Hong Kong biotech start-up says its first-phase trial of a therapeutic HIV vaccine has shown promising results. Photo: dpa
Biomedicine: Geopolitics

Chinese biotech firms brace for Trump tariffs, US funding bill

Efforts to expand sales of high-value products in China and non-US markets would cushion the blow, analysts say.

Hong Kong

Vaccine shows promise in curing HIV, Hong Kong start-up says

‘We may be on the brink of a breakthrough,’ Dr Edward Leong, advisory board chairman of Immuno Cure says.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement